Palvella Therapeutics (PVLA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $120.30, -5.53% vs the prior close of $127.34.
- Volume 179.49K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PVLA slides 5.5% to $120.30, a 3-month low. Closed at $120.30, -5.53% vs the prior close of $127.34. Day range $118.22–$127.27, opened at $127.27.
PVLA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PVLA slides 5.5% to $120.30, a 3-month low
- Closed at $120.30, -5.53% vs the prior close of $127.34. Day range $118.22–$127.27, opened at $127.27.
- Volume was 179.49K shares, 0.8x its 50-day average of 212.21K.
- Price is -17.3% vs its 50-day average ($145.45) and -3.9% vs its 200-day average ($125.20).
- 52-week range $68.96–$161.38; today's close sits at 56% of that range, 25.5% below the 52-week high.
Oct 15, 2026 — PVLA jumps 3.9% to $127.34
- Closed at $127.34, +3.88% vs the prior close of $122.58. Day range $122.51–$129.49, opened at $123.58.
- Volume was 241.00K shares, 1.1x its 50-day average of 210.33K.
- Price is -12.9% vs its 50-day average ($146.14) and +1.8% vs its 200-day average ($125.10).
- 52-week range $68.96–$161.38; today's close sits at 63% of that range, 21.1% below the 52-week high.
Oct 14, 2026 — PVLA slides 4.6% to $122.58, a 3-month low on 1.8x normal volume
- Closed at $122.58, -4.61% vs the prior close of $128.51. Day range $120.27–$128.29, opened at $125.53.
- Volume was 382.30K shares, 1.8x its 50-day average of 208.27K — unusually heavy trading.
- Price is -16.4% vs its 50-day average ($146.70) and -1.9% vs its 200-day average ($124.97).
- 52-week range $68.96–$161.38; today's close sits at 58% of that range, 24.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — PVLA slides 4.4% to $128.51
- Closed at $128.51, -4.37% vs the prior close of $134.38. Day range $127.97–$134.14, opened at $134.08.
- Volume was 215.80K shares, 1.0x its 50-day average of 206.87K.
- Price is -12.7% vs its 50-day average ($147.28) and +2.9% vs its 200-day average ($124.88).
- 52-week range $66.58–$161.38; today's close sits at 65% of that range, 20.4% below the 52-week high.
Oct 12, 2026 — PVLA slides 3.2% to $134.38
- Closed at $134.38, -3.16% vs the prior close of $138.77. Day range $131.78–$138.48, opened at $137.27.
- Volume was 213.40K shares, 1.0x its 50-day average of 206.31K.
- Price is -8.9% vs its 50-day average ($147.53) and +7.7% vs its 200-day average ($124.76).
- 52-week range $65.93–$161.38; today's close sits at 72% of that range, 16.7% below the 52-week high.
Oct 9, 2026 — PVLA jumps 5.7% to $138.77, 3 up days in a row
- Closed at $138.77, +5.66% vs the prior close of $131.34. Day range $128.80–$139.86, opened at $130.70.
- Volume was 174.00K shares, 0.8x its 50-day average of 205.99K.
- Price is -6.0% vs its 50-day average ($147.62) and +11.4% vs its 200-day average ($124.59).
- 52-week range $65.93–$161.38; today's close sits at 76% of that range, 14.0% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — PVLA rises 0.6% to $131.34
- Closed at $131.34, +0.57% vs the prior close of $130.59. Day range $124.49–$131.95, opened at $129.90.
- Volume was 209.30K shares, 1.0x its 50-day average of 204.48K.
- Price is -11.2% vs its 50-day average ($147.85) and +5.5% vs its 200-day average ($124.44).
- 52-week range $65.93–$161.38; today's close sits at 69% of that range, 18.6% below the 52-week high.
Oct 7, 2026 — PVLA rises 2.0% to $130.59
- Closed at $130.59, +2.02% vs the prior close of $128.00. Day range $125.00–$131.35, opened at $125.97.
- Volume was 152.00K shares, 0.7x its 50-day average of 204.41K.
- Price is -11.8% vs its 50-day average ($148.08) and +5.1% vs its 200-day average ($124.28).
- 52-week range $65.93–$161.38; today's close sits at 68% of that range, 19.1% below the 52-week high.
Oct 6, 2026 — PVLA slides 3.1% to $128.00, a 1-month low, 6 down days in a row
- Closed at $128.00, -3.15% vs the prior close of $132.16. Day range $124.97–$133.85, opened at $133.75.
- Volume was 309.40K shares, 1.5x its 50-day average of 201.70K.
- Price is -13.7% vs its 50-day average ($148.32) and +3.1% vs its 200-day average ($124.11).
- 52-week range $65.93–$161.38; today's close sits at 65% of that range, 20.7% below the 52-week high.
- That makes 6 straight losses.
Oct 5, 2026 — PVLA ends flat (-0.2%) to $132.16, a 1-month low, 5 down days in a row
- Closed at $132.16, -0.23% vs the prior close of $132.47. Day range $129.51–$133.26, opened at $132.50.
- Volume was 140.60K shares, 0.7x its 50-day average of 202.57K.
- Price is -11.1% vs its 50-day average ($148.60) and +6.6% vs its 200-day average ($123.93).
- 52-week range $61.73–$161.38; today's close sits at 71% of that range, 18.1% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — PVLA ends flat (-0.2%) to $132.47, a 1-month low, 4 down days in a row
- Closed at $132.47, -0.20% vs the prior close of $132.73. Day range $127.26–$137.04, opened at $135.15.
- Volume was 348.10K shares, 1.8x its 50-day average of 198.30K.
- Price is -10.9% vs its 50-day average ($148.71) and +7.0% vs its 200-day average ($123.76).
- 52-week range $60.49–$161.38; today's close sits at 71% of that range, 17.9% below the 52-week high.
- That makes 4 straight losses.
PVLA latest news & SEC filings
Every SEC filing by or about PVLA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Jenkins George M sold 5,095 shares at $132.62 (≈$675.68K) on Oct 12, 2026; now holds 155,021
- Jenkins George M sold 2,458 shares at $133.25 (≈$327.52K) on Oct 12, 2026; now holds 152,563
- Jenkins George M sold 3,335 shares at $134.21 (≈$447.59K) on Oct 12, 2026; now holds 149,228
- Jenkins George M sold 1,447 shares at $135.50 (≈$196.06K) on Oct 12, 2026; now holds 147,781
- Jenkins George M sold 817 shares at $136.44 (≈$111.48K) on Oct 12, 2026; now holds 146,964
- Jenkins George M sold 2,004 shares at $128.52 (≈$257.56K) on Oct 13, 2026; now holds 144,960
- …plus 11 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Goin Kathleen converted options/RSUs into 2,154 shares at $7.14 (≈$15.38K) on Sep 16, 2026; now holds 2,154
- Goin Kathleen converted options/RSUs into 2,148 shares at $9.08 (≈$19.50K) on Sep 16, 2026; now holds 4,302
- Goin Kathleen sold 1,659 shares at $151.16 (≈$250.77K) on Sep 16, 2026; now holds 2,643
- Goin Kathleen sold 989 shares at $152.36 (≈$150.69K) on Sep 16, 2026; now holds 1,654
- Goin Kathleen sold 1,654 shares at $153.24 (≈$253.46K) on Sep 16, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 16, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Jenkins George M sold 560 shares at $151.33 (≈$84.74K) on Sep 15, 2026
- Jenkins George M sold 954 shares at $149.38 (≈$142.51K) on Sep 15, 2026
- Jenkins George M sold 263 shares at $150.40 (≈$39.56K) on Sep 15, 2026
- Jenkins George M sold 560 shares at $151.33 (≈$84.74K) on Sep 15, 2026
- Jenkins George M sold 954 shares at $149.38 (≈$142.51K) on Sep 15, 2026
- Jenkins George M sold 263 shares at $150.40 (≈$39.56K) on Sep 15, 2026
- …plus 7 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 11, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 4, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$21.87M (prior year -$9.47M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.52 (prior year -$0.86) (loss widened vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 3, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade PVLA
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 31, 2026, Feb 24, 2026. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.89% (largest 5.7%).
- Liquidity: about 226.38K shares (≈$27.23M) trade per day on average.
- 52-week position: $120.30 vs a range of $68.96–$161.38 (56% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Kathleen Goin sold 1,654 shares on Sep 16, 2026.
- Latest filings: 10-Q Aug 4, 2026; 8-K Aug 4, 2026; 8-K Jul 14, 2026.
- Share count: 14.41M shares outstanding (Jul 31, 2026), +30.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PVLA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 127.27 | 127.27 | 118.22 | 120.30 | 179.49K |
| Oct 15, 2026 | 123.58 | 129.49 | 122.51 | 127.34 | 241.00K |
| Oct 14, 2026 | 125.53 | 128.29 | 120.27 | 122.58 | 382.30K |
| Oct 13, 2026 | 134.08 | 134.14 | 127.97 | 128.51 | 215.80K |
| Oct 12, 2026 | 137.27 | 138.48 | 131.78 | 134.38 | 213.40K |
| Oct 9, 2026 | 130.70 | 139.86 | 128.80 | 138.77 | 174.00K |
| Oct 8, 2026 | 129.90 | 131.95 | 124.49 | 131.34 | 209.30K |
| Oct 7, 2026 | 125.97 | 131.35 | 125.00 | 130.59 | 152.00K |
| Oct 6, 2026 | 133.75 | 133.85 | 124.97 | 128.00 | 309.40K |
| Oct 5, 2026 | 132.50 | 133.26 | 129.51 | 132.16 | 140.60K |
| Oct 2, 2026 | 135.15 | 137.04 | 127.26 | 132.47 | 348.10K |
| Oct 1, 2026 | 135.57 | 139.23 | 131.65 | 132.73 | 337.40K |
| Sep 30, 2026 | 141.14 | 142.96 | 137.30 | 137.93 | 262.30K |
| Sep 29, 2026 | 140.20 | 141.54 | 136.18 | 139.00 | 214.80K |
| Sep 28, 2026 | 138.13 | 143.55 | 137.43 | 139.83 | 188.60K |
| Sep 25, 2026 | 147.02 | 147.44 | 137.86 | 138.16 | 193.30K |
| Sep 24, 2026 | 148.05 | 149.11 | 143.08 | 146.07 | 185.10K |
| Sep 23, 2026 | 157.62 | 157.62 | 147.43 | 149.56 | 180.60K |
| Sep 22, 2026 | 155.08 | 160.84 | 153.64 | 158.13 | 276.60K |
| Sep 21, 2026 | 152.40 | 155.11 | 151.31 | 153.41 | 123.60K |
About Palvella Therapeutics
Palvella Therapeutics (PVLA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WAYNE, PA. State of incorporation: NV. Fiscal year ends December 31. SEC CIK 1583648.
PVLA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Todd C Davis | Director | Jun 12, 2026 |
| John Doux | Director | Jun 12, 2026 |
| Elaine J Heron | Director | Jun 12, 2026 |
| George M Jenkins | Director | Sep 15, 2026 |
| Christopher P Kiritsy | Director | Sep 4, 2026 |
| Wes Kaupinen | President and CEO | Feb 9, 2026 |
| Matthew Pauls | Director | Jul 1, 2026 |
| Tadd S. Wessel | Director | Jun 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kathleen Goin | Chief Operating Officer | Sep 18, 2026 |
| Wes Kaupinen | President and CEO | Feb 9, 2026 |
| Ashley Hartmann Kline | Chief Commercial Officer | Feb 9, 2026 |
| Matthew E Korenberg | CFO, Treasurer | Jun 16, 2026 |
| Jeffrey S Martini | Chief Scientific Officer | Feb 9, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 16, 2026 | Kathleen Goin | Sale | 1,654 | $153.24 |
| Sep 16, 2026 | Kathleen Goin | Sale | 989 | $152.36 |
| Sep 16, 2026 | Kathleen Goin | Sale | 1,659 | $151.16 |
| Sep 16, 2026 | Kathleen Goin | Sale | 1,654 | $153.24 |
| Sep 16, 2026 | Kathleen Goin | Sale | 989 | $152.36 |
| Sep 16, 2026 | Kathleen Goin | Sale | 1,659 | $151.16 |
| Sep 16, 2026 | Kathleen Goin | Sale | 1,654 | $153.24 |
| Sep 16, 2026 | Kathleen Goin | Sale | 989 | $152.36 |
| Sep 16, 2026 | Kathleen Goin | Sale | 1,659 | $151.16 |
| Sep 16, 2026 | Kathleen Goin | Sale | 1,654 | $153.24 |
| Sep 16, 2026 | Kathleen Goin | Sale | 989 | $152.36 |
| Sep 16, 2026 | Kathleen Goin | Sale | 1,659 | $151.16 |
| Sep 15, 2026 | George M Jenkins | Sale | 560 | $151.33 |
| Sep 15, 2026 | George M Jenkins | Sale | 954 | $149.38 |
| Sep 15, 2026 | George M Jenkins | Sale | 263 | $150.40 |
PVLA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-41.72M | -3.71 | $-25.01M |
| Dec 31, 2024 | — | $-17.43M | -7.83 | $-10.84M |
| Dec 31, 2023 | — | $18.69M | 2.17 | $-13.70M |
| Dec 31, 2022 | — | $-33.28M | — | $-59.93M |
| Dec 31, 2021 | — | $-45.74M | -0.71 | $-7.66M |
Latest balance sheet: total assets $253.51M, total liabilities $36.64M, cash $187.80M (as of Jun 30, 2026).
PVLA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $151.99 |
| May 7, 2026 | 8-K Item 2.02 (results) | $113.26 |
| Mar 31, 2026 | 8-K Item 2.02 (results) | $124.65 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $120.41 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $80.29 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $46.10 |
| May 15, 2025 | 8-K Item 2.02 (results) | $21.61 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $27.99 |
| Mar 27, 2024 | 8-K Item 2.02 (results) | — |
| Jul 18, 2023 | 8-K Item 2.02 (results) | — |
| Jun 21, 2023 | 8-K Item 2.02 (results) | — |
| May 10, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PVLA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.